Nanotech Immune Stimulant (NIS) Shows Promising Prevention of Parahaemolyticus Vibrio Disease in Shrimp Aquaculture
August 21 2013 - 3:09PM
Nano Labs Corp. (OTCQB:CTLE) is pleased to report today the results
of testing of its proprietary Nanotechnology Immune Stimulant (NIS)
which prevents the propagations of infections made by Vibrio
Parahaemolyticus, a bacteria that cause disease in cultured shrimp.
Nano Lab's innovative solution is a Nanotech Immune Stimulant
(NIS), which modulates the response of the immune system in shrimp.
Tests conducted in partnership with CIBNOR, Bioassay Project No
960-0, shows the NIS increases the number of immune cells, and a
considerable reduction of the proliferation rate of the
bacteria.
Nano Labs and CIBNOR are pleased to report the following first
round of results from the commercial pilot program.
The NIS was incorporated in the shrimp feed at various
concentrations where the shrimps were fed daily at libitum up to 30
days. The daily administration of the NIS ranged in concentrations
of 0 μg NIS / gram of feed (for the control tank) up to 500 μg NIS
/ gram of feed across six (6) treatment tanks. The treatment tanks
contained three hundred (300) shrimp per tank and the mortality
rate was recorded daily on the total 1,800 shrimp infected with the
Parahaemolyticus Vibrio.
The percentage of shrimp survival after direct infection was 15%
and 20% at 500 ug NIS / gram of feed. Further, the trials showed
there is no health risk to the shrimp and the product does not
affect shrimp larval development or survival.
"The laboratory preliminary numbers show promising results for
shrimp at the levels tested and these dosages are effective against
Parahaemolyticus Vibrio. The NIS has remarkable antibacterial
activity towards the bacteria when it is incorporated in the
culture media at concentrations over 10%," states Dr. Victor
Castano, Chief Innovations Officer at Nano Labs. "Further tests are
required that compare the effectiveness of our nanotech immune
stimulant with other products available on the market as a
antibacterial cocktail, as Parahaemolyticus Vibrio affects 30% of
worldwide shrimp production. We are continuing to develop and test
the product with the goal of achieving a 100% survival rate."
The shrimp aquaculture industry
Aquaculture is the fastest growing food production sector in the
world and has been established as an important source of protein to
meet food demand worldwide because the natural resources are now
overexploited. But at present, the biggest problem facing the
aquaculture industry worldwide, are the diseases caused by various
biological and non-biological agents. Among the groups of
microorganisms that cause serious losses in shrimp farming, the
best known are bacteria due to the devastating effects they have on
affected farms. Bacterial diseases are mainly due to Vibrio, which
have been reported in the penaeid shrimp culture systems and
implicates at least 14 species, and among them the Parahaemolyticus
Vibrio is one of the most lethal. Its effects caused massive
epidemics in Thailand and the Philippines in the early 90's and now
it represents a worldwide problem.
Vibriosis is one of the major disease problems in aquaculture
seafood and fish. Vibriosis is a bacterial disease responsible for
mortality of cultured shrimp worldwide. Vibriosis is present
throughout the world and in all marine crustaceans, including
shrimps which are the most susceptible.
The shrimp aquaculture industry has grown at a rate of 10% per
year for the last decade, producing over 4 million tons of shrimp
in 2011, with an estimated total value of 15 billion USD for the
global shrimp market. Shrimp exports in 2012 brought Vietnam over
2.23 USD billion despite losses of 373 million USD due to the White
Spot Virus in 2010.
Despite this positive growth, the shrimp aquaculture industry
faces challenges related to increasing hazards in biosecurity,
production costs and overall sustainability. Infectious diseases,
especially from microorganisms, are a leading problem and expansion
of the industry has been greatly hindered by the presence of these
diseases, which negatively affect worldwide production.
Additional Information
Companies, organizations or governments interested in requesting
a copy of the Full Report, are invited to contact Mr. Bernardo
Camacho Chavarria, President of Nano Labs.
Additional information on the Company's Joint Venture with
CIBNOR can be found in the Company's press release of June 11, 2013
here,
http://nanolabs.us/press-releases/nano-labs-announces-joint-venture-with-cibnor/.
For more information on CIBNOR, please visit
www.cibnor.com.mx.
About Nano Labs Nano Labs Corp. (CTLE) is a
nanotechnology research and development company which began in
October, 2012, but is able to access resources that encompass
nearly 30 years of research and development in nanotechnology as
well as hundreds of peer-reviewed and published research papers and
other scholarly material. Our Company's research and development
team of scientists, designers, and engineers is focused on creating
a portfolio of advanced products that could provide benefits to a
variety of industries including: (i) consumer products, (ii)
energy, (iii) materials, and (iv) healthcare. Through the use and
integration of proprietary nano compounds, our goal is to evolve
common products into new, revolutionary products in order to make
the world a better place. Nano Labs shares are traded on the OTC
Bulletin Board in the United States under the ticker CTLE. For more
information, please visit www.NanoLabs.us.
The Nano Labs Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=16293
Forward looking statements
This press release contains forward-looking information within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1993 and Section 21E of
the Securities Exchange Act of 1934 and is subject to the safe
harbor created by those laws. These forward-looking statements are
based upon a number of assumptions and estimates that are subject
to significant uncertainties that involve known and unknown risks,
many of which are beyond our control and are not guarantees of
future performance. Actual outcomes and results could materially
differ from what is expressed, implied, or forecasted in any such
forward-looking statements and any such difference may be caused by
risk factors listed from time to time in the Company's news
releases and/or its filings with the OTC Bulletin Board or as a
result of other factors.
CONTACT: Nano Labs Corp.
Bernardo Camacho Chavarria
President
bernardo@nanolabs.us
1 (888) 806-2315